vs
Axsome Therapeutics, Inc.（AXSM）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Axsome Therapeutics, Inc.的季度营收约是Proto Labs Inc的1.4倍（$191.2M vs $139.3M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs 10.4%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs 5.3%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
AXSM vs PRLB — 直观对比
营收规模更大
AXSM
是对方的1.4倍
$139.3M
营收增速更快
AXSM
高出47.0%
10.4%
两年增速更快
AXSM
近两年复合增速
5.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $191.2M | $139.3M |
| 净利润 | — | $8.1M |
| 毛利率 | — | 45.6% |
| 营业利润率 | -33.1% | 7.1% |
| 净利率 | — | 5.8% |
| 营收同比 | 57.4% | 10.4% |
| 净利润同比 | — | 125.4% |
| 每股收益（稀释后） | — | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMPRLB
| Q1 26 | $191.2M | $139.3M | ||
| Q4 25 | $196.0M | $136.5M | ||
| Q3 25 | $171.0M | $135.4M | ||
| Q2 25 | $150.0M | $135.1M | ||
| Q1 25 | $121.5M | $126.2M | ||
| Q4 24 | $118.8M | $121.8M | ||
| Q3 24 | $104.8M | $125.6M | ||
| Q2 24 | $87.2M | $125.6M |
净利润AXSMPRLB
| Q1 26 | — | $8.1M | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $7.2M | ||
| Q2 25 | $-48.0M | $4.4M | ||
| Q1 25 | $-59.4M | $3.6M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $7.2M | ||
| Q2 24 | $-79.3M | $4.5M |
毛利率AXSMPRLB
| Q1 26 | — | 45.6% | ||
| Q4 25 | — | 44.2% | ||
| Q3 25 | — | 45.3% | ||
| Q2 25 | — | 44.3% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 45.6% | ||
| Q2 24 | — | 45.0% |
营业利润率AXSMPRLB
| Q1 26 | -33.1% | 7.1% | ||
| Q4 25 | -13.8% | 5.0% | ||
| Q3 25 | -27.0% | 6.5% | ||
| Q2 25 | -24.5% | 3.7% | ||
| Q1 25 | -46.9% | 3.6% | ||
| Q4 24 | -61.1% | -1.2% | ||
| Q3 24 | -59.8% | 6.8% | ||
| Q2 24 | -89.5% | 4.8% |
净利率AXSMPRLB
| Q1 26 | — | 5.8% | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 5.3% | ||
| Q2 25 | -32.0% | 3.3% | ||
| Q1 25 | -48.9% | 2.9% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 5.7% | ||
| Q2 24 | -91.0% | 3.6% |
每股收益（稀释后）AXSMPRLB
| Q1 26 | — | $0.29 | ||
| Q4 25 | $-0.55 | $0.25 | ||
| Q3 25 | $-0.94 | $0.30 | ||
| Q2 25 | $-0.97 | $0.18 | ||
| Q1 25 | $-1.22 | $0.15 | ||
| Q4 24 | $-1.54 | $-0.01 | ||
| Q3 24 | $-1.34 | $0.29 | ||
| Q2 24 | $-1.67 | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $305.1M | $124.0M |
| 总债务越低越好 | $70.0M | — |
| 股东权益账面价值 | — | $683.1M |
| 总资产 | $713.6M | $778.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMPRLB
| Q1 26 | $305.1M | $124.0M | ||
| Q4 25 | $322.9M | $128.1M | ||
| Q3 25 | $325.3M | $119.2M | ||
| Q2 25 | $303.0M | $103.2M | ||
| Q1 25 | $300.9M | $96.8M | ||
| Q4 24 | $315.4M | $103.1M | ||
| Q3 24 | $327.3M | $100.5M | ||
| Q2 24 | $315.7M | $112.9M |
总债务AXSMPRLB
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益AXSMPRLB
| Q1 26 | — | $683.1M | ||
| Q4 25 | $88.3M | $673.9M | ||
| Q3 25 | $73.7M | $664.7M | ||
| Q2 25 | $73.1M | $664.7M | ||
| Q1 25 | $53.2M | $656.8M | ||
| Q4 24 | $57.0M | $670.2M | ||
| Q3 24 | $92.9M | $680.0M | ||
| Q2 24 | $102.9M | $685.2M |
总资产AXSMPRLB
| Q1 26 | $713.6M | $778.6M | ||
| Q4 25 | $689.8M | $763.4M | ||
| Q3 25 | $669.3M | $756.9M | ||
| Q2 25 | $639.8M | $743.3M | ||
| Q1 25 | $596.7M | $737.5M | ||
| Q4 24 | $568.5M | $743.5M | ||
| Q3 24 | $561.5M | $753.8M | ||
| Q2 24 | $548.2M | $758.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $17.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 2.16× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AXSMPRLB
| Q1 26 | — | $17.5M | ||
| Q4 25 | $-18.7M | $16.5M | ||
| Q3 25 | $1.0M | $29.1M | ||
| Q2 25 | $-32.4M | $10.6M | ||
| Q1 25 | $-43.4M | $18.4M | ||
| Q4 24 | $-26.2M | $17.3M | ||
| Q3 24 | $-18.6M | $24.8M | ||
| Q2 24 | $-30.1M | $14.4M |
自由现金流AXSMPRLB
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $8.4M | ||
| Q3 25 | $988.0K | $25.0M | ||
| Q2 25 | $-32.4M | $9.1M | ||
| Q1 25 | $-43.7M | $17.1M | ||
| Q4 24 | $-26.2M | $16.5M | ||
| Q3 24 | $-18.7M | $23.2M | ||
| Q2 24 | $-30.2M | $10.2M |
自由现金流率AXSMPRLB
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 6.2% | ||
| Q3 25 | 0.6% | 18.5% | ||
| Q2 25 | -21.6% | 6.7% | ||
| Q1 25 | -36.0% | 13.6% | ||
| Q4 24 | -22.1% | 13.5% | ||
| Q3 24 | -17.9% | 18.5% | ||
| Q2 24 | -34.6% | 8.2% |
资本支出强度AXSMPRLB
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.3% | 1.0% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.1% | 3.3% |
现金转化率AXSMPRLB
| Q1 26 | — | 2.16× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 4.03× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 5.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | — | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
